1. Alisporivir for use in the treatment of hepatitis C virus-infected genotype 1 African American patient, characterized in that alisporivir should be administered in an amount of from about 400 to about 600 mg twice a day. Alisporivir for use according to claim 1, characterized in that alisporivir should be administered in combination with standard drugs or a direct antiviral agent. Alisporivir for use according to claim 1 or 2, characterized in that alisporivir should be administered for up to 24 or 48 weeks. Alisporivir for use according to claim 2, wherein the standard drugs are a combination of interferon and ribavirin. 5. Alisporivir for use according to claim 4, wherein said interferon is pegylated interferon alpha-2a, and it is administered in an amount of 180 micrograms once a week. Alisporivir for use according to claim 2, wherein said direct-acting antiviral agent is ANA598.7. A method of treating an African American patient of genotype 1 hepatitis C virus infection, comprising administering alisporivir in an amount of about 400 to about 600 mg twice daily for up to 24 or 48 weeks, and optionally administering to the patient standard drugs or a direct antiviral agent. . The use of alisporivir in the manufacture of a medicament for the treatment of hepatitis C virus-infected genotype 1 African American patient, characterized in that alisporivir should be administered in an amount of from about 400 to about 600 mg twice a day for up to 24 or 48 weeks, optionally, with alisp �1. Алиспоривир для применения в лечении инфицированного вирусом гепатита C генотипа 1 пациента афроамериканца, отличающийся тем, чтоалиспоривир следует вводить в количестве от примерно 400 до примерно 600 мг два раза в сутки.2. Алиспоривир для применения по п. 1, отличающийся тем, что алиспоривир следует вводить в сочетании со стандартными лекарственными средствами или противовирусным средством прямого действия.3. Алиспоривир для применения по п. 1 или 2, отличающийся тем, что алиспорив
